The tumor -suppressor gene p16INK4 / CDKN2 ( p16 ) is a cyclin -dependent kinase ( cdk ) inhibitor and important cell cycle regulator. Here, we show that adenovirus -mediated gene transfer of p16 ( AdCMV.p16 ) into colon cancer cells induces uncoupling of S phase and mitosis and subsequently apoptosis. Flow cytometric analysis revealed that cells infected with AdCMV.p16 showed an initial G2 -like arrest followed by S phase without intervening mitosis ( DNA >4N ). Using microscopic analysis, deformed polyploid cells were detectable only in cells infected with AdCMV.p16 but not in control -infected cells. Subsequently, AdCMV.p16 -infected polyploid cells underwent apoptosis, as assessed by AnnexinV staining and DNA fragmentation, suggesting that cell cycle dysregulation is upstream of the onset of apoptosis. Treatment of mice with subcutaneously transplanted tumors of colorectal cancer cells with AdCMV.p16 but not AdCMV.p53 resulted in significantly reduced tumor volume and prolonged survival. Using an orthotopic model of liver metastasis, we observed both reduced local tumor growth and secondary intrahepatic metastasis after AdCMV.p16 treatment. Importantly, induction of apoptosis in vitro and reduction of tumor growth in vivo by p16 was p53 -as well as bax -independent because identical results were obtained using cancer cells, either wild type or mutant for p53 or bax. The studies suggest that an AdCMV.p16 -based treatment may be especially effective in patients with bax -negative colon cancer where overexpression of p53 appears not to be of therapeutic value.
C olorectal cancer is the second leading cause of cancer mortality in most Western countries. 1 -3 Early stages are treated surgically, with high curability. However, locally advanced cases and patients with distant metastases at diagnosis share a very poor prognosis. Recurrence following surgery, which occurs in 50-65% of the cases, is a major problem especially in patients with lymph -node -positive disease and often the ultimate cause of death. 1, 4 An estimated 50,000 patients continue to die annually of this disease in the United States, two-thirds of whom will have liver metastases as their first site of disease dissemination and 40% of whom will have liver as the only site of metastatic disease. 1, 2 Response rates to systemic therapy have remained in the range of 25 -40%, with median survival times in the range of 10 -15 months. 1, 5, 6 Therefore, colon cancer represents an important target for new therapeutic strategies.
Over the last years it became evident from studies of patients with hereditary forms of colon cancer ( hereditary nonpolyposis colorectal cancer ) that besides the known causes for neoplastic growth due to mutations in either proto -oncogenes or tumor-suppressor genes there exists a third class of genes that can contribute to tumor growth when mutated. These genes encode enzymes involved in DNA mismatch repair and their mutational inactivation leads to genomic instability, which results in frameshift mutations of short nucleotide repeat sequences called microsatellites. 7, 8 Whereas this microsatellite mutator phenotype affects repeat sequences throughout the genome, some appear to be preferentially targeted. One of these targets is the bax gene, a promoter of apoptosis, which is frequently mutated in patients of the mutator phenotype. 9 The absence of bax has been correlated with poor prognosis in nonhereditary colon cancer. 10, 11 Currently, most cancer gene therapy studies employ the transfer of tumor-suppressor genes like p53 12, 13 or the transfer of genes that activate prodrugs into active chemotherapeutic agents ( e.g., herpes simplex virus thymidine kinase/ ganciclovir system ). 14 -17 In addition, immunological approaches are under investigation using the transfer of cytokine genes like IL-2 or IL -12, 18 -20 tumor specific antigens like CEA, 21 -24 or costimulatory molecules like B7 -1 25, 26 to induce tumor regression. Adenoviral vectors are mostly used for these experiments because they have a tropism for a broad range of cell types, can be produced at high titers leading to a higher transduction efficiency, and infect both dividing and nondividing cells. 27 The tumor suppressor p16 is a member of the INK4 family of cyclin -dependent kinase (cdk ) inhibitor proteins. 28 P16 inhibits cdk4 and cdk6, which promote cell cycle progression through G1 phase by phosphorylation of the retinoblastoma gene product (Rb ). Inhibition of cdk4 and cdk6 by plasmidborne p16 leads to hypophosphorylated Rb, which, in turn, blocks cell cycle transition from G1 to S phase. 29 -31 In addition, p16 plays a role in the regulation of apoptosis. Adenovirus-mediated overexpression of p16 was reported to be cytotoxic to p53 + cancer cells, 29 and p16 sensitized p53+ carcinoma cells to proapoptotic stimuli. 32, 33 Adenoviral gene transfer of p16 was shown to induce inhibition of tumor growth and apoptosis in vitro. 32 -34,36,37 Moreover, adenoviral delivery of p16 may reduce the metastatic potential of tumor cells in vitro. 38 Interestingly, p16 is often mutated or deleted in tumor cell lines and primary tumors. 39 -43 Other mechanisms of p16 gene silencing have been described, including hypermethylation and chromatin condensation. 44 -46 Mutations in the p16 gene are strongly associated with tumorigenesis because mice that are nullizygous for p16 develop spontaneous tumors. 35 The aim of this study was to elucidate the potential clinical significance of adenovirus -mediated overexpression of p16 protein in bax -negative colon carcinoma cells as a means of blocking metastatic disease in vivo. We demonstrate that adenovirus -mediated overexpression of exogenous p16 induces apoptosis in colon cancer cells as a result of uncoupling of S phase and mitosis (S /M uncoupling ). This effect was caused by an initial G2 -like arrest followed by S phase without intervening mitosis and subsequent p53-independent apoptosis. Significant inhibition of tumor growth could be observed in vivo. Using an orthotopic in vivo model of liver metastasis, we show that the intratumoral application of p16 by adenovirus -mediated gene transfer results in inhibition of local tumor growth and intrahepatic metastasis as well as prolonged survival in a p53/ baxpathway-independent manner. Hence, the data support clinical studies employing adenovirus -mediated gene transfer of the cdk inhibitor p16 in patients with bax -negative colon cancer where overexpression of p53 appears not to be effective therapeutically.
Material and methods

Cell lines and cell culture
All cell lines were purchased from ATCC. The human colon carcinoma cell lines LS174T and SW620 were maintained in RPMI 1640; LoVo and 293 cells (human embryonal kidney ) were cultured in DMEM. Both media were supplemented with 10% fetal calf serum (FCS ) and 2 mM glutamine. Cells were cultured at 378C in a humidified atmosphere of 5% CO 2 . The cell lines LoVo and LS174T express wild -type p53 and p21 but are negative for the expression of bax or p16 (Fig 3  and data not shown ) . 9, 47, 48 The SW620 cells line express mutant p53 but wild -type p21, bax, and p16 (data not shown ). 11, 49 In accordance with institutional guidelines, human hepatocytes were isolated from normal liver wedge resections by collagenase -P (Roche Diagnostics, Grenzau, Germany ) digestion as recently described. 50, 51 Briefly, after enzymatic digestion hepatocytes were separated from nonparenchymal cells by differential centrifugation at 50Âg and then passed over a 30% Percoll (Pharmacia, Freiburg, Germany ) gradient at a concentration of 10 6 cells / mL Percoll to obtain a highly purified cell population. Hepatocyte purity and viability assessed by microscopy was greater than 95% and viability consistently exceeded 90% by trypan blue exclusion. 51 The primary hepatocytes were cultured in Williams Medium E, supplemented with 10% heat -inactivated (90 minutes at 708C ) FBS, 1% penicillin /streptomycin, 15 mM Hepes buffer (all Life Technologies, Karlsruhe, Germany ), 2.0 g /mL insulin, and 0.35 nM hydrocortisone ( both Sigma, Deisenhofen, Germnay ) at 378C, 5% CO 2 in a humidified atmosphere.
Construction and propagation of recombinant adenovirus vector
The replication -deficient recombinant adenovirus (Ad vector ) constructs carry the cDNAs of p16 (AdCMV.p16), p21 (AdCMV.p21), or p53 (AdCMV.p53 ) and E. coli -galactosidase ( AdCMV. -gal ), respectively, under the control of the cytomegalovirus (CMV ) promoter, as described. 32, 52, 53 The Ad vector AdRSV-hAAT.2 carries the cDNA of the human alpha -1 antitrypsin, driven by the Rous sarcoma virus promoter ( RSV ). 54 All vectors were propagated on 293 cells, purified, and stored at À 708C, as described previously. 55, 56 Each vector preparation was tested for the presence of replication competent virus by a modified supernatant rescue assay. Briefly, 5Â10 5 nonpermissive cells ( LoVo) were infected with 50 multiplicity of infection ( MOI ) of the respective vector and incubated for 6 days with medium change on day 4. DNA was isolated from aliquots of the culture supernatant and assayed by PCR for the presence of sequences from the E1a and E4 regions of the adenoviral genome. Only vector batches that were tested twice negative for E1a were subsequently used for experiments. Flow cytometric analysis of apoptosis and cell cycle A total of 8Â10 5 cells were seeded in triplicates in 10 -cm dishes. Twenty-four hours later, cells were infected with various Ad vectors at the indicated MOI as described. 53 Cells were harvested by trypsinization at the indicated time points. For detection of apoptosis, cells were stained with FITCconjugated AnnexinV and propidium iodide (PI ) using a commercial kit ( Immunotech, Marseille, France ) as described by the manufacturer. Samples were subsequently analyzed by flow cytometry (FACScan, Becton -Dickinson, San Jose, CA ) for the presence of viable (FITC -negative and PI -negative ) and apoptotic (FITC -positive and PInegative) cells. For analysis of cell cycle distribution, FITCAnnexinV -stained samples were fixed and permeabilized as described. 57, 58 Briefly, after washing two times with PBS, a pellet of 5Â10 5 cells was fixed after addition of 2 mL icecold 70% ethanol for 1 hour at 48C. After washing, cells were resuspended in 0.5 mL PBS containing 50 g/ mL PI ( pH 7.5 ). After treatment with 10 l of 10 mg /mL RNase A ( Boehringer Mannheim, Mannheim, Germany ) at room temperature in the dark for 30 minutes, cells were stored at 48C until flow cytometric analysis. Cell cycle analysis was performed using CellQuest software (Becton Dickinson ).
Detection of intracellular transgene expression
Microscopic analysis of apoptosis
Apoptosis was assessed microscopically using an immunoperoxidase -based detection kit for digoxigenin -labeled DNA strand breaks as described by the manufacturer ( ApopTag 1 Plus In Situ Apoptosis Detection Kit, ONCOR, Gaithersburg, MD ) with the following modifications: On slides, cells (5Â10 5 cells ) were air-dried and incubated with 4% paraformaldehyde for 10 minutes at room temperature. After washing three times with PBS, cells were incubated in 0.1% Triton X -100 for 10 minutes at room temperature. Cells were washed again three times with PBS, then the manufacturers protocol was followed.
Animal studies
C.B17 /BlnA -Scid /Scid mice (SCID mice ) were obtained from the animal core facility at the Max Delbrück Center ( Berlin, Germany ). Mice of the same sex, age ( 8-10 weeks ) and weight (20 - 6 cells / mm 3 . Animals were inspected daily and the subcutaneous tumors were measured twice per week. In the orthotopic model, the mice were killed and autopsied before they reached the final cachectic phase. The size of the tumor at the injection site was measured as well as the number and size of metastases determined separately for the remainder of the liver and extrahepatic sites.
Results
AdCMV.p16 leads to efficient gene transfer of p16 into colon cancer cells in vitro
To confirm Ad vector -mediated overexpression of the transgene, we performed immunocytological staining for p16 24 hours after infection of LoVo colon cancer cells. Due to hypermethylation of its promoter region, LoVo cells are negative for p16 expression at the mRNA and protein level ( Fig 1C and data not shown) . 47, 48 No p16 expression was detectable in control -vector -infected ( Fig 1B ) or mocktreated cells ( Fig 1C) , whereas AdCMV.p16-infected cells stained strongly positive for p16 (Fig 1A ) .
Adenovirus -mediated overexpression of p16 leads to a G2 / M -like arrest in vitro
Endogenous p16 is well known to induce G1 arrest by binding and inhibiting cdk4 and cdk6. 28 To study the effects of Ad vector -mediated overexpression of p16 ( AdCMV. p16) on cell cycle in colon cancer cells, LoVo cells were Cancer Gene Therapy p16 induces cell cycle alteration and apoptosis in colon cancer I Tamm et al infected with either AdCMV.p16, AdCMV.p21, various reporter-gene constructs (AdRSV-hAAT.2, AdCMV.-gal ), or treated with medium alone (mock ). Because Ad vector infection itself can induce a modest reduction of cells in G1 phase compared to mock -treated cells, 37, 59 the effects of AdCMV.p16 and AdCMV.p21 were analyzed as change of cell cycle distribution compared to an irrelevant reporter gene construct ( AdRSV-hAAT.2 ). Flow cytometric analysis revealed that infection with AdCMV.p16 resulted in a dramatic reduction of cells in the G1 phase of cell cycle after 96 hours, which was paralleled by a corresponding increase of cells in G2 / M phase compared to control -infected and mock -treated cells ( Fig 2) and data not shown ). In contrast to AdRSV-hAAT.2 -infected cells, infection with AdCMV. p21 led to a sustained G1 arrest (Fig 2 ) .
Adenovirus -mediated overexpression of p16 causes apoptosis downstream of AdCMV.p16 -induced cell cycle dysregulation in colon cancer cells but not in normal hepatocytes
AdCMV.p16-infection of colon cancer cells resulted in a significantly higher number of apoptotic cells ( P <.001 ) ( Fig 3C ) compared to control -infected (AdRSV-hAAT2, AdCMV.p21, Fig 3, B and D ) or mock -treated (Fig 3A ) samples, as assessed by a TUNEL -based assay. Similar results were obtained when apoptosis was assessed using AnnexinV staining ( data not shown ). To exclude cytotoxic effects on nonmalignant cells after Ad vector -mediated gene transfer, we performed additional studies using human primary hepatocytes. No significant differences in viability between AdCMV.p16, AdCMV.p21, and control (AdCMV.
-gal, AdRSV-hAAT2 ) infected or mock -treated nonmalignant human hepatocytes were observed suggesting that AdCMV.p16 is nontoxic to normal liver tissue, at least at the MOI (20 -50) tested in the experiments (Fig 3E and data  not shown ) .
To elucidate the AdCMV.p16-mediated proapoptotic effects on colon cancer cells in more detail, we analyzed AdCMV.p16 -infected nonapoptotic cells separately using flow cytometry (Fig 4, A -C ) . Cells infected with AdCMV. p16 accumulated significantly more hyperdiploid cells with a DNA content >4N ( Fig 4C ) compared to control -infected ( Fig 4B ) or mock -treated ( Fig 4A ) cells. When the entire cell population was analyzed, the occurrence of hyperdiploid cells was accompanied by a substantial increase in the number of apoptotic cells (DNA content < G1 ) ( Fig 4F ) . No Cancer Gene Therapy p16 induces cell cycle alteration and apoptosis in colon cancer I Tamm et al significant apoptosis was detectable in control -vectorinfected ( Fig 4E ) or mock -treated ( Fig 4D ) cells. In parallel, using microscopic analysis of nonapoptotic colon carcinoma cells, we detected deformed polyploid nuclei exclusively in cells infected with AdCMV.p16 but not in control -infected cells. Furthermore, only polyploid cells underwent apoptosis suggesting that cell cycle deregulation preceded cell death (data not shown ). Thus, colon carcinoma cells can be killed effectively by Ad vector -mediated overexpression of p16. Following transient arrest in G2 /M phase, infection with AdCMV.p16 induces uncoupling of S phase from subsequent mitosis ( S /M uncoupling ) leading to polyploid cells ( N >4 ) and, finally, cell death by apoptosis.
Induction of apoptosis by AdCMV.p16 is independent of the genetic status of p53 and bax
The tumor-suppressor gene p53 is an important upstream regulator of cell cycle and apoptosis. 28 Because p53 is mutated in approximately 50% of malignant tumors 10, 11 and its downstream effector bax is also frequently mutationally inactivated, a gene therapy construct to be effective clinically should function in a p53/ bax-independent manner. We investigated whether the observed effects of AdCMV.p16 are p53 -and bax-independent. For these experiments we used two colon carcinoma cell lines: LoVo cells are wild -type p53 ( p53 wt ) but bax negative (bax neg) and SW620 cells are p53 mutant (p53 mut ) and wild -type bax ( bax wt ) (data not shown). 9, 47, 49 Using the same experimental procedures as described above for LoVo cells, SW620 cells were infected with AdCMV.p16 or control vectors and subjected to cell cycle analysis. Again, the analysis of nonapoptotic subpopulations revealed that hyperdiploid cells (DNA content >4N ) were exclusively observed in cells infected with AdCMV.p16 but not in mock -treated or control -infected cells. The occurrence of hyperdiploid cells was accompanied by a substantial increase in the number of apoptotic cells ( DNA content < G1 ) when the entire cell population was analyzed. Because identical results were obtained in LoVo ( p53 wt /bax neg) and SW620 cells ( p53 mut /bax wt ), the data suggest that AdCMV.p16 is capable of inducing apoptosis by S/ M uncoupling independently of the genomic p53 status ( data not shown). Moreover, because LoVo cells are deficient for bax, AdCMV.p16 is able to induce apoptosis in cells independently of the p53/ bax proapoptotic pathway.
Adenovirus -mediated gene transfer of p16 inhibits tumor growth of colon cancer cells in vitro and prolongs survival in tumor -bearing mice
To analyze whether induction of apoptosis by S /M uncoupling after Ad vector -mediated gene transfer of p16 may also be effective in inhibiting tumor growth in vivo, we injected 1Â10 6 p53 wt /bax neg LoVo cells or p53 mut /bax wt SW620 subcutaneously into SCID mice. After 14 days, the resulting tumors were subjected to in vivo gene transfer by a single intratumoral injection of Ad viruses at an MOI of 30. In contrast to various control viruses ( AdRSV-hAAT.2, AdCMV. -gal ) or mock treatment, intratumoral administration of AdCMV.p16 resulted in a substantially reduced growth of both p53 wt /bax neg (Fig 5A and data not shown) and p53 mut / bax wt tumors ( Fig 5B and data not shown ) . In addition, as suggested by our in vitro experiments (Figs 2 and 3 ), adenovirus -mediated gene transfer of another cdk inhibitor, p21, did not inhibit tumor growth compared to control vectors (data not shown). Further support for the observation that inhibition of tumor growth by AdCMV.p16 overexpression is independent of p53-mediated proapoptotic signaling in vivo comes from experiments where p53 Cancer Gene Therapy p16 induces cell cycle alteration and apoptosis in colon cancer I Tamm et al wild type, but bax-negative LS174T colon cancer cells were investigated in an analogous xenotransplant model. A single injection of 30 MOI AdCMV.p16 into subcutaneous tumors led to a substantially reduced tumor growth in mice ( Fig 6) . In contrast, neither treatment with AdCMV. -gal, AdCMV.p53, nor AdCMV.p21 significantly inhibited tumor growth. All AdCMV.p16-treated animals were alive at day 83 (end of the experiment ). In contrast, all mice in the control groups had to be euthanized until day 35 due to tumor growth. Histological examination of the remaining tumors in AdCMV.p16-infected mice revealed only very few tumor cells within fibrotic tissue. Adenovirally mediated expression of the transgene was detectable in xenograft tumors for 80 days ( data not shown ). These results demonstrate that adenovirus -mediated gene transfer of p16, but not of p21 or p53, by single intratumoral injection induces a significant reduction of tumor growth in both p53-mutant but bax -positive and p53 -wild type but baxnegative tumors in vivo. Most importantly, AdCMV.p16 increased overall survival in tumor-bearing mice compared to control vectors.
Adenovirus -mediated gene transfer of p16 inhibits tumor growth in an orthotopic model of liver metastasis in vivo
Two -thirds of patients with colorectal cancer will have liver metastases as their first site of disease dissemination and 40% of whom will have liver as the only site of metastatic disease.
1,2 Because liver metastases can be targeted by direct intratumoral injection, they represent a reasonable target for gene therapy strategies in vivo. To further investigate whether AdCMV.p16 infection of liver metastases from colon cancer can block secondary metastasis in vivo, we designed an orthotopic murine model of liver metastasis by xenotransplantation of 1Â10 6 LoVo colon cancer cells into the tip of the left lateral lobe of the liver. At day 5, hepatic tumors were either injected with 30 MOI of adenoviral vectors AdCMV.p16, control vector ( AdRSV-hAAT.2 ), or mock treated. Tumor size at the site of injection and tumor volume of all liver metastases were evaluated when the animals were sacrificed (before they reached the final cachectic phase ).
Intratumoral administration of AdCMV.p16 significantly inhibited local hepatic tumor growth compared to control LoVo cells ( 1Â10 6 cells per animal ) were injected in the tip of the left lateral lobe of the liver of SCID mice. Five days after inoculation, Ad vectors ( 30 MOI ) were administered intratumorally. When the mice were sacrificed, the number of extrahepatic metastases was assessed by whole -body autopsy of tumor -challenged animals as described in Materials and methods. The percentages of animals with metastases according to the affected anatomic site are given. Eleven / twelve animals were used per experimental / mock group. ( Fig 7A and data not shown) as well as secondary intrahepatic metastases (Fig 7B and data not shown ) . All mock -treated and control -vector -infected mice developed secondary liver metastases as assessed by macroscopic evaluation. In contrast, only 18% of animals injected with AdCMV.p16 developed secondary liver metastases ( data not shown). Moreover, we observed a dramatic reduction in the number of extrahepatic metastases in p16 -infected mice in comparison to control animals, as assessed by whole body autopsy of tumor-challenged animals ( Table 1 ) . For example, peritoneal carcinogenesis developed in 0%, 27%, and 33% of p16, alpha -1 antitrypsin, and mock -treated animals, respectively. These results suggest that adenovirusmediated gene transfer of p16 blocks hepatic tumor growth and metastatic disease in vivo.
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Discussion
Among the different approaches to treat colon cancer by gene therapy is the ''replacement strategy'' where a mutated or deleted tumor-suppressor gene is substituted by its corresponding wild -type counterpart. 60 The classical candidate gene is p53, which plays a central role in the regulation of cell cycle and apoptosis. 28 The latter is mediated, at least in part, by transcriptional activation of the proapoptotic bax gene. 61 However, as demonstrated by frame shift mutations of bax in colon cancer of the mutator phenotype, 9 p53-controlled proapoptotic pathways may be blocked in tumor cells and this blockade cannot be overcome by overexpression of p53 as shown here in LS174T cells ( bax neg ) in vivo ( Fig 6 ) . Thus, in addition to results from other gene therapy studies, 28 our data provide further evidence that alternative strategies are needed to improve the efficacy of in vivo gene therapy for tumors expressing wild -type p53 and mutated bax.
Selective induction of apoptosis using transfer of proapoptotic genes like bax, 62 apoptin, 63 or caspases 64,65 directly into tumor cells in vivo appears to be a promising treatment strategy. However, a therapeutic effect using this approach requires intact downstream signal transduction pathways. Unfortunately, death effectors like proapoptotic bax 9 or caspases 66 are frequently mutated in tumor cells potentially blocking the therapeutic effect. Gene transfer of cdk inhibitors like p16 into tumor cells is a promising alternative antitumor approach that has been tested by several groups. 32, 37, 60, 67, 68 There are several advantages to choose p16 as therapeutic gene. We show that intratumoral application of AdCMV.p16 was superior to p53 or p21 in controlling local tumor growth. The strong antitumor effect of AdCMV.p16 was detectable as long as 12 weeks after a single intratumoral application, resulting in a prolonged survival of AdCMV.p16-treated animals. Moreover, we detected AdCMV.p16 -induced apoptosis in both p53 wt LoVo and p53 mut SW620 colon cancer cells, suggesting that AdCMV.p16 -induced cell death is independent of the genomic p53 status. Similar antitumor effects after overexpression of AdCMV.p16 were seen in LS174T cells, which are like LoVo wild type for p53, but negative for bax, suggesting that AdCMV.p16-induced apoptosis is also independent of proapoptotic signaling pathways downstream of p53, i.e., pathways including bax. Our data underline the significance of adenoviral vectors overexpressing members of the p16/ Rb /E2F regulatory pathway such as E2F -1 69 or p16 as a means of bypassing p53 -/bax -dependent apoptosis in vitro and bax-negative colon cancer in vivo, respectively. Similar to p53, p16 is frequently altered in human cancers and represents a multifunctional key element in cell cycle regulation and apoptosis. 28 Regarding the latter, coinfection of AdCMV.p16 and AdCMV.p53 has been shown to be cytotoxic to Rb + cancer cells and to induce apoptosis. However, the underlying mechanism remains elusive. 29, 32 After infection of LoVo colon cancer cells with AdCMV.p16, we observed accumulation of infected cells in G2 /M phase, subsequent S phase without intervening mitosis and, finally, apoptosis, as assessed by AnnexinV staining and DNA fragmentation. Our data suggest that S /M uncoupling is located upstream of apoptotic cell death and may represent a mechanism of how AdCMV.p16 induces cell death in the infected tumor cell.
Because of their ability to inhibit phosphorylation and inactivation of Rb by cyclin /cdk complexes and their ability thereby to induce a G1 growth arrest, the various cdk inhibitors are potential therapeutic tumor suppressors. 37 After infection of colon cancer cells with AdCMV.p16, we observed only a transient G1 arrest, which was followed by a G2 -like block. The well -known ability of p16 to induce G1 arrest by binding and inhibiting cdk4 and cdk6 is usually seen in experiments employing either endogenous or plasmid -born p16. In contrast, we used adenovirusmediated overexpression of p16 resulting in G2 arrest and apoptosis, which may be caused by the intracellular interaction of adenovirus and transgene. However, this effect may also be dependent on the employed cell lines since Schreiber et al observed cells accumulating in G2 /M after adenovirus -mediated expression of various INK4 family members in MT1A2 cells, but not in A549 cells, where the same experimental procedure resulted in a G1 arrest. 37 The authors were able to correlate the ability of the cdk inhibitors to inhibit pRb phosphorylation in the different cell lines with their ability to arrest cells in G1. 37 In another study, mRNA and protein levels of INK4 family members were found to oscillate during the cell cycle, accumulating during S phase and remaining high throughout G2 /M. 70 In response to nonlethal ultraviolet irradiation, HeLa cells accumulated elevated levels of p16. The accumulation of p16 correlated with S phase and G2 delays. The UV-induced cell cycle delay was absent in cell lines derived from HeLa that did not express p16 and in a melanoma cell line deleted for p16. 71 Thus, p16 may play an important role during later stages of the cell cycle and its proapoptotic effects seem to depend on an adenoviral delivery. 37 It has been shown that Ad virus infection of cells can cause cell cycle dysregulation, which is characterized by a G2 -like cell cycle arrest and deregulated expression of cyclins A, B1, D, and cdk p34cdc2 protein levels. 59, 72 However, the cell cycle disturbances observed in our experiments were clearly due to the overexpression of p16 and not the adenoviral infection itself because irrespective of the genomic status of p16, p53, p21, or bax of tumor cells, infection with various control vectors did not induce significant cell cycle disturbances and apoptosis.
To investigate adenovirus -mediated gene transfer of p16 as a potential new treatment option for bax -negative metastatic colon cancer, we used an orthotopic model of liver metastasis in SCID mice. Similar to the results of the subcutaneous tumor model, in vivo gene transfer of p16, but neither of p21 nor of p53, was superior to control vectors in inhibiting secondary liver metastasis. Most strikingly, we observed a significantly reduced number of metastases in other organs as well. Thus, the proapoptotic effect of AdCMV.p16 in vitro is paralleled by an antitumor effect in vivo. In concordance with other in vivo models, 37, 68 the animal studies presented in this paper demonstrate a low toxicity of p16 in vivo, because infection of normal hepatocytes with p16 did not cause more apoptosis than control vector or mock treatment, suggesting that the clinical application of this treatment approach should be safe. The ability to promote cell death is not a universal property of all cdk inhibitors because expression of p21 did not induce apoptosis in cancer cells either in vitro or in vivo. In fact, various researchers reported that p21 has a protective effect against apoptosis induced by p53 as well as other stimuli. 37, 73, 74 In addition, despite extensive searches, only very few tumors have been shown to have mutations in their p21 genes, 75 and mice null for p21 develop normally with no increased incidence of neoplasia. 76 In our hands, only p16 inhibited tumor growth in vivo, demonstrating that the cdk inhibitors vary in their ability to promote cell death. Kim et al reported that adenoviral -mediated overexpression of wildtype p16 in vitro induces cell death more efficiently in cancer cells expressing mutant forms of p16 than in cancer cell lines with wild -type p16. 33 At variance with other cdk inhibitors like p21, 75 mutations within the p16 gene and loss of p16 expression are frequent events observed in both tumor cell lines and in various carcinomas including colon cancer. 77, 78 The proapoptotic effect and expression pattern of p16 in various cancer cells in vivo make adenovirus -mediated gene substitution of this cdk inhibitor an interesting new therapeutic option for cancer gene therapy. The mechanisms for the proapoptotic effects of p16 may include the activation of specific caspases as a direct or indirect result of cell cycle disturbances at the G2 -restriction point. 33 ,79 It will be interesting to further analyze the connection between cell cycle regulation and cell death. Recently, an antiapoptotic protein, survivin, which blocks caspase activity in vitro, has been shown to free cdk4 from its inhibitor p16 by directly binding cdk4. 80 -82 Thus, survivin appears to be a new and potentially important protein bridging cell cycle and apoptosis regulation. 79 The combination of different cdk inhibitors in one adenovirus vector may be more effective in killing tumor cells than each of the cdk inhibitors alone. Patel et al showed that an adenovirus containing p16 and p27 activities (AV-W9 ) was more effective in inducing apoptosis than either of the molecules alone. 83 AV-W9 elicited apoptosis in numerous tumor cell lines at doses that were 5-to 10 -fold lower than those required for AV-p16 and AV-p27 alone. In addition, the superiority of AV-W9 was demonstrated in a murine tumor-therapy model.
In summary, we demonstrate for the first time that overexpression of exogenous p16 induces apoptosis in baxnegative colon cancer cells as a result of uncoupling of S phase and mitosis (S /M uncoupling ). AdCMV.p16 infection is safe, applicable, and highly efficient in inhibiting liver metastases of colon cancer in a p53/ bax-pathway -independent manner. Moreover, even a single injection of AdCMV.p16 is capable of controlling tumor growth and metastasis, which is accompanied by a prolonged survival of tumor-challenged animals. These results indicate that AdCMV.p16 but not overexpression of p53 holds significant promise as a therapeutic agent especially for patients with bax-negative colon cancer with metastatic disease or at high risk of relapse after first -line therapy.
